In a randomized, double-blinded, placebo-controlled trial, the single oral dose typhoid vaccine, M01ZH09, is safe and immunogenic at doses up to 1.7 x 10(10) colony-forming units

• Published in: Vaccine Vol. 28; no. 20; pp. 3602 - 3608
• Main Authors: Lyon, C E, Sadigh, K S, Carmolli, M P, Harro, C, Sheldon, E, Lindow, J C, Larsson, C J, Martinez, T, Feller, A, Ventrone, C H, Sack, D A, DeNearing, B, Fingar, A, Pierce, K, Dill, E A, Schwartz, H I, Beardsworth, E E, Kilonzo, B, May, J P, Lam, W, Upton, A, Budhram, R, Kirkpatrick, B D
• Format: Journal Article
• Language: English
• Published: Netherlands 30-04-2010
• Subjects: Adolescent; Adult; Antibodies, Bacterial - blood; Double-Blind Method; Female; Humans; Immunoglobulin A - blood; Immunoglobulin G - blood; Male; Middle Aged; Typhoid Fever - prevention & control; Typhoid-Paratyphoid Vaccines - administration & dosage; Typhoid-Paratyphoid Vaccines - immunology; Vaccines, Attenuated - administration & dosage; Vaccines, Attenuated - immunology; Young Adult
• ISSN: 1873-2518
• DOI: 10.1016/j.vaccine.2010.02.017

M01ZH09, S. Typhi (Ty2 Delta aroC Delta ssaV) ZH9, is a single oral dose typhoid vaccine with independently attenuating deletions. A phase II randomized, double-blind, placebo-controlled, dose-escalating trial evaluated the safety and immunogenicity of M01ZH09 to 1.7 x 10(10) colony-forming units (CFU). 187 Healthy adults received vaccine or placebo in four cohorts. Serologic responses and IgA ELISPOT were measured. At all doses, the vaccine was well tolerated and without bacteremias. One subject had a transient low-grade fever. 62.2-86.1% of subjects seroconverted S. Typhi-specific LPS IgG and 83.3-97.4% IgA; 92.1% had a positive S. Typhi LPS ELISPOT. M01ZH09 is safe and immunogenic up to 1.7 x 10(10)CFU. Efficacy testing of this single-dose oral typhoid vaccine is needed.